

---

 DIGEST

The digest printed below was prepared by House Legislative Services. It constitutes no part of the legislative instrument. The keyword, one-liner, abstract, and digest do not constitute part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]

---

SB 253 Reengrossed

2026 Regular Session

McMath

Proposed law provides that no professional or occupational licensing board shall prohibit a healthcare provider with prescriptive authority from providing patients with peptides shipped from either of the following:

- (1) A FDA-registered 503B outsourcing facility that is in compliance with 21 U.S.C. 353b.
- (2) A 503A compounding pharmacy that is in compliance with 21 U.S.C. 353a and applicable United States Pharmacopeia - National Formulary chapters.

Proposed law provides that no professional or occupational licensing board shall prohibit a La. licensed pharmacist in a state permitted pharmacy from compounding and dispensing peptides as long as the pharmacist and pharmacy are in compliance with 21 U.S.C. 353a and applicable United States Pharmacopeia - National Formulary chapters.

Effective August 1, 2026.

(Adds R.S. 37:23.5)

Summary of Amendments Adopted by Senate

Committee Amendments Proposed by Senate Committee on Health and Welfare to the original bill

1. Extends provisions of proposed law to compounding pharmacies.

Senate Floor Amendments to engrossed bill

1. Changes references to the federal requirements that apply to prescribing providers, pharmacists, and compounding pharmacies.

Summary of Amendments Adopted by House

The Committee Amendments Proposed by House Committee on Health and Welfare to the reengrossed bill:

1. Remove the provision for prescribing providers to ensure that any peptides prescribed pursuant to the proposed law are prepared in accordance with FDA or United States Code regulations.
2. Make technical changes.